Brequinar and dipyridamole in combination exhibits synergistic antiviral activity against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19Research article Published on 2022-10-012022-10-05 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 변종, 치료법, 치료제, [키워드] acute respiratory syndrome Antiviral antiviral activity Antiviral treatment B.1.351 B.1.617.2 Beta Brequinar cellular Combination coronavirus coronavirus disease COVID-19 de novo deaths Delta DHODH Dihydroorotate dehydrogenase (DHODH) Dipyridamole drug treatments effective enzyme evade Evolution of SARS-CoV-2 exhibit global pandemic Host host cell in vitro Infection infections inhibitor maintain medical need monoclonal antibody nucleotide pathway rationale Replication required resulting RNA virus SARS-CoV-2 SARS-COV-2 infection selective shown Support synergistic therapy treat Treatment Vaccine variants viral replication [DOI] 10.1016/j.antiviral.2022.105403 [Article Type] Research article
Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysisObservational Study Published on 2021-11-012022-10-05 Journal: Journal of thrombosis and haemostasis : JTH [Category] SARS, 임상, [키워드] absolute reduction Analysis antiplatelet antiplatelet therapy Aspirin association average baseline calculated clopidogrel Cohort Comorbidities Comorbidity Controlled trial Coronavirus disease 2019 COVID-19 demographics determine Dipyridamole groups health system Hemorrhagic Hospitalized hypercoagulability In-hospital death in-hospital mortality laboratory-confirmed Mortality no difference Observational cohort study Patient patient population patients patients hospitalized patients with COVID-19 prasugrel Prevent receive receiving resulting SARS-CoV-2 significantly lower survival The United States therapy Thrombotic complications thrombotic risk ticagrelor. treated utility [DOI] 10.1111/jth.15517 PMC 바로가기 [Article Type] Observational Study
Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors디피리다몰, 클로로퀸, 몬테루카스트 나트륨, 칸데사르탄, 옥시테트라사이클린 및 아타자나비르는 SARS-CoV-2 주요 프로테아제 억제제가 아닙니다Comment Published on 2021-02-232022-09-10 Journal: Proceedings of the National Academy of Sciences of [Category] 치료제, [키워드] candesartan Chloroquine Dipyridamole inhibitor SARS-CoV-2 main protease sodium [DOI] 10.1073/pnas.2024420118 PMC 바로가기 [Article Type] Comment
No Time to Waste: Real-World Repurposing of Generic Drugs as a Multifaceted Strategy Against COVID-19Viewpoint Published on 2020-09-302022-10-29 Journal: Jmirx Med [Category] COVID-19, [키워드] absence Against antagonists Anti-inflammatory anticoagulation antiplatelet Antiviral bezafibrate Cimetidine COVID-19 COVID-19 crisis COVID-19 pandemic Dipyridamole drug drug candidate Drug repurposing drugs example expand Famotidine Fenofibrate Fibrates Generic histamine type-2 receptor antagonists inhibitor off-label pathophysiology patients patients with COVID-19 physician public health receptor Repository repurposing Safe Sildenafil Strategy Support supported time Treatment [DOI] 10.2196/19583 PMC 바로가기 [Article Type] Viewpoint
[SARS-CoV-2 (COVID-19) as a predictor of neuroinflammation and neurodegeneration: potential therapy strategies]Article Published on 2020-01-012023-07-05 Journal: Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova [Category] SARS, [키워드] Cognitive impairment Cytokine storm Dipyridamole neurodegeneration Neuroinflammation potential therapy strategies. SARS-CoV-2 coronavirus [DOI] 10.17116/jnevro202012008258 PMC 바로가기